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ABSTRACT
HS-40 is the major regulatory element of the human
α-globin locus, located 40 kb upstream of the ζ-globin
gene. To test for potential interactions between HS-40
and the β- or the γ-globin gene promoters in stable
transfection assays, the HS-40 core sequence was
cloned upstream of either the β promoter or the γ
promoter driving the neomycin phosphotransferase
gene and enhancer activity was measured using a
colony assay. In K562 or in MEL cells, enhancer activity
of HS-40 was higher than that of the individual core
sequences of the DNase I hypersensitive sites (HS) of
the β-globin locus control region (LCR), and ∼60% of
the enhancer activity of a 2.5 kb µLCR, which contains
the core elements of DNase I hypersensitive sites 1–4.
In contrast to the synergistic interaction between the
DNase I hypersensitive sites of β locus LCR, combination of HS-40 with these DNase I hypersensitive sites
failed to display cooperativity in K562 cells and
inhibited enhancer function in MEL cells. Inhibition of
enhancer function was also observed when two copies
of the HS-40 were arranged tandemly. We conclude
that the core element of HS-40 (i) is a powerful
enhancer of γ- and β-globin gene expression, (ii) in
contrast to other classical enhancers, acts best as a
single copy, (iii) does not cooperate with the regulatory
elements of the β-globin locus control region.
INTRODUCTION
Effective gene replacement therapy for the human hemoglobinopathies will require consistent high level expression of the
transferred globin gene within a significant population of
erythroid precursor cells. Initial expression studies utilizing
native β-globin gene promoter and enhancer elements resulted in
inconsistent and very low level expression (1,2). In 1987,
Grosveld et al. (3) described the human β locus control region
(LCR) as an element composed of five DNase I hypersensitive
sites (HS) located 6–20 kb upstream of the ε-globin gene. These
authors also showed that the LCR activates the β-globin locus
domain, it is a powerful globin gene enhancer, it directs erythroid
lineage specific expression of linked genes and it protects the

globin genes from position effect of the surrounding chromatin
(3,4). The discovery of the β-globin LCR raised hopes that this
element could provide consistent, high level expression in
virally-mediated gene transfer. Although combinations of LCR
elements are able to confer such expression in transgenic mouse
models (3,4), consistent, near-endogenous levels of expression
have been much more difficult to achieve in retroviral or other
viral gene transfer systems (5–7). Indeed, the inclusion of LCR
elements within globin expressing retroviruses does not appear to
result in position-independent expression (5). The development
of retroviral vectors containing the active elements of the globin
LCR has also been complicated by difficulties in obtaining high
titer producer cell lines and by genetic rearrangement of the
viruses (8,9). While recent reports of improved LCR-containing
retroviral vectors are encouraging, these vectors have yet to
achieve adequate expression in pre-clinical models to justify
human therapeutic trials (10).
An alternative approach to achieving consistent high-level
expression from a transferred human β-globin gene is to
incorporate regulatory elements from genes other than those of
the β-globin locus which are also expressed at high levels in
erythroid cells. One example of such a set of genes is the human
α-globin genes. While the α-globin genes are expressed at levels
equivalent to the human β-globin gene, their expression appears
to be regulated, at least in part, by a different mechanism. In
contrast to the β-globin locus, the major distant regulator of the
α-globin locus is marked by a major DNase I hypersensitve site
located ∼40 kb 5′ of the embryonic α-globin gene (the ζ-globin
gene) and it is designated as the HS-40 element (11). Natural
deletion mutations suggest that the HS-40 element is required for
normal expression of the α-globin genes (12,13). In contrast to
the β-globin LCR, the HS-40 element does not confer positionindependent expression of linked genes in transgenic mice, nor
does it appear to be required for the organization of the chromatin
structure of the α-globin locus (14,15). HS-40 also differs from
the LCR in that it is contained within a single element of ∼350 bp
(16); in contrast, the functional activity of the β-globin LCR is
contained within four elements which are widely separated within
the β-globin LCR (3,17). The ability of HS-40 to direct high level
expression in transgenic mice, its small size, and a mechanism of
action apparently distinct from that of the β locus LCR make it a
prime candidate to be a transcriptional enhancer useful in the
construction of therapeutic β-globin gene transfer vectors.
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To assess the ability of HS-40, alone or in combination with
regulatory elements of the LCR, to function as a transcriptional
enhancer of expression from globin promoters we have used the
colony assay of Moon and Ley (18). This assay has the advantage
of allowing rapid assessment of enhancer function within a
chromatin context. We have applied this assay to study the
enhancer activity of the HS-40 element in a variety of experimental situations. We found that a single HS-40 core element
displays enhancer activity nearly equivalent to that of an LCR
cassette (nanoLCR) containing the core elements of HS2, HS3
and HS4 of the β-globin LCR. We also found that, in contrast to
individual DNase I hypersensitive sites of the β locus LCR which
increase globin gene expression in a synergistic fashion, HS-40
fails to cooperate with either the nanoLCR or with the individual
LCR elements; constructs containing combinations of HS-40
with β locus LCR elements actually exhibit decreased enhancer
activity. Similarly, a tandem arrangement of HS-40 elements
results in decreased enhancer activity. These results provide
additional evidence that the α-globin locus HS-40 is functionally
distinct from the β-globin locus LCR and that it may be useful in
the development of therapeutic globin gene vectors.
MATERIALS AND METHODS
Constructs
The original γ-neo and β-neo vectors were obtained from Dr
T.Ley (Washington University, St Louis, MO) (18,19). The γ
promoter consists of a 335 bp AluI fragment extending from –299
to +36 with respect to the transcription initiation site of the
Aγ-globin gene. The β promoter consists of a 421 bp AccI–NcoI
fragment extending from –375 to +46 with respect to the
transcription initiation site of the β-globin gene. A 2.34 kb
HindIII neomycin resistance (neoR) fragment was cloned
downstream of the globin promoter as a reporter gene. The
transcription cassette was excised from the original vectors with
BamHI, and subcloned to NotI site of pBluescript vector. The
original HS-40 containing plasmid (pBS-αLCR) used in this
study was obtained from Dr G.Atweh (Mount Sinai School of
Medicine, New York, NY) (20). 255 bp HS-40 core was excised
from pBS-αLCR with EcoRV and BamHI, and cloned upstream
of γ-neo and β-neo at the EcoRV site (HS-40–γ-neo and
HS-40–β-neo). 5′ sequence of 255 bp HS-40 core is
5′-TCTGGAACCTATCAGGGAC-3′, and the 3′ end sequence of
HS-40 core is 5′-CTCTCAGATAAACAGGAGGGGG-3′ (20).
2× HS-40–γ-neo and 2× HS-40–β-neo recombinants were
generated by inserting another copy of 255 bp HS-40 core at
upstream ClaI site of HS-40–γ-neo and HS-40–β-neo. HS-40 +
HS1–γ-neo was generated by inserting 255 bp HS-40 at ClaI site
upstream of the HS1–γ-neo which contains 316 bp HS1
(13104–13419) of the β-LCR. HS-40 + HS1–β-neo was similarly
constructed. HS-40 + HS2–γ-neo was constructed by inserting
HS-40 at SalI site upstream of the HS2–γ-neo which contains
371 bp HS2 (8485–8855) of the β-LCR. HS-40 + HS2–β-neo
was similarly cloned. The 1.1 kb nLCR cassette is generated by
combining 282 bp of HS4 (942–1223), 426 bp of HS3
(4348–4773) and 371 bp HS2 (8485–8855) of the β-LCR
together (21). nLCR–γ-neo and nLCR–β-neo were made by
inserting nLCR cassette at the KpnI and EcoRV sites upstream of
the γ-neo or β-neo. nLCR–HS-40–γ-neo was constructed by
inserting nLCR cassette at the ClaI site upstream of the

HS-40–γ-neo. nLCR–HS-40–β-neo was similarly constructed.
For cloning HS-40–γ-neo–HS-40 and HS-40–β-neo–HS-40, the
HS-40 fragment was inserted at the SacII site 3′ of the neomycin
phosphotransferase gene of the HS-40–γ-neo or HS-40–β-neo.
All HS-40 core derivatives were sequenced by the dideoxynucleotide method (22) to verify that the constructs were correctly
made. Control plasmids µLCR–β-neo and µLCR–γ-neo were
provided by Dr T.Ley (Washington University, St Louis). Plasmid
DNA was prepared with PEG precipitation method to large
quantity. DNA was linearized with ScaI and further purified for
transfection experiments.
Tissue culture
Murine Erythroleukemia (MEL) cells and human K562 cells
were maintained in RPMI 1640 (GIBCO Laboratories, Grand
Island, NY) containing 10% fetal bovine serum (FBS) (GIBCO),
heat-inactivated at 56C for 30 min. Cells were cultured at 37C
in 5% CO2 with 100% humidity.
Lipofection
DNA transfection was done by performing lipofection by a
modified procedure of Dorman and Yang (23,24). Cells were
washed twice with serum-free medium-RPMI 1640 for erythroid
cell lines. For each erythroid cell transfection, 7 µg of linearized
plasmid DNA and 50 µg of Lipofectin reagent (GIBCO) were
each added to 1.5 ml of serum-free medium. The DNA and
lipofectin solutions were mixed, vortexed, and added to 107 cells.
Cells were incubated for 6 h at 37C, at which time 7 ml of
medium containing 20% FBS was added. Cells were collected
24 h later by centrifugation and added to 20 ml of fresh medium
containing 10% FBS. Cells were grown for another 24 h and
G418 (GIBCO) at 0.7 mg/ml was added.
Colony assays
Cells were grown under G418 selection and plated in different
conditions. For K562 cells, 2 × 105 cells were plated per 10 cm
Petri dish in semi-soft agar. For MEL cells, 106 cells were seeded
in 96-well flat bottom plate and grown in suspension. Ten to 14
days later, visible colonies were quantitated in triplicate plates.
Chromatin structure analysis
Pools of transfected clones were selected and expanded in G418.
DNase I sensitivity assays were performed as previously
described (25). For Southern blotting, constructs were excised
from genomic DNA using restriction enzyme sites present within
the pbluescript SK backbone. These included SmaI or KpnI
located immediately 5′ of the construct and SmaI or DraI located
3′ of the construct. The probe used in these experiments was a 900
bp EcoRI/HindIII fragment from the 3′ end of the neoR gene (26).
The EcoRI site is within the gene and the HindIII site from an
adjacent polylinker.
RESULTS
To characterize the enhancer function of the HS-40, we examined
the activity of the 255 bp long HS-40 core sequence shown in
Figure 1A. Enhancer activity was assessed using the colony assay
of Moon and Ley (18,19). This assay measures enhancer activity
by quantitating the neomycin-resistant colonies produced by
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Figure 1. (A) Schematic representation of the human α-globin cluster and the transcriptional motifs present in the 255 bp HS-40 core element. (B) Diagrams of the
HS-40–β-neo and HS-40–γ-neo constructs used for colony assays. Arrows indicate the genomic orientation (from 5′ to 3′) of the core sequences of DNase I the
hypersensitive sites of the β locus LCR.

MEL or K562 cells transfected with HS-40 (or LCR) containing
constructs. Since only a threshold level of neomycin phosphotransferase is required for colony surviral, any interaction
between enhancer and promoter resulting in production of the
minimal amount of the enzyme required for cell survival, results
in formation of a viable colony. The number of colonies so formed
provides a measure of enhancer strength (18,19).
The γ-neo recombinant contains a neomycin phosphotransferase gene linked to a γ gene promoter extending 299 bp upstream
of the transcription initiation site and containing +36 bp of the 5′
untranslated region (GeneBank Humhbb.gb_pr 39133–39431).
The β gene promoter of the β-neo recombinant extends 375 bp
upstream of the transcription initiation site and contains +46 bp
of the untranslated region (61784–62154). The sequences of the
γ and β gene promoters contain all the cis elements required for
optimal γ or β gene transcription (27,28). We included two
control plasmids in our assays, µLCR–β-neo and µLCR–γ-neo,
both containing a 2.5 kb LCR cassette consisting of sequences of
the DNase I hypersensitive sites 1, 2, 3 and 4. The enhancer
activity of the 2.5 kb µLCR was given the arbitrary value of 100%
and all of our data were expressed as a percentage of the number
of colonies produced by the µLCR-containing constructs.
The interaction between HS-40 and the β-globin gene promoter
was investigated by transfecting the recombinant genes into the
mouse erythroleukemia cell line MEL585. These cells are
committed to the adult stage of erythropoiesis and produce only
adult murine globins. The interaction between HS-40 and the
γ-globin promoter was examined in the human erythroleukemia
cell line K562. These cells express high level of γ-globin, small
amount of ε-globin and no adult (β)-globin.
Interactions of HS-40 with the β- and γ-globin promoters
To characterize the interaction of HS-40 with the β- or γ-globin
promoter, we inserted the 255 bp HS-40 core sequence upstream
of the β- or γ-globin promoter (Fig. 1B). In MEL 585 cells, the

Figure 2. Interactions of HS-40 with the β gene promoter and regulatory
elements of the β locus LCR. The β-neo-containing constructs were transfected
into MEL cells. The number of colonies produced by the transfected MEL cells
is expressed as percent of the number of colonies produced by the control
µLCR–β-neo construct. (A) β-neo construct with no enhancer. (B) HS-40–β-neo.
(C) HS-40–HS1–β-neo. (D) HS-40–HS2–β-neo. (E) HS-40–nLCR–β-neo.
(F) nLCR–β-neo. The nanoLCR is composed of the core sequences of HS2, HS3
and HS4. Notice that HS-40 displays as high enhancer activity as the nLCR
[compare (B) to (F)]. Also notice that the HS-40 fails to cooperate with HS1, HS2
or the nLCR.

number of colonies produced by a control β-neo construct which
did not contain an enhancer was 0.4% ± 0.3 of the number of
colonies produced by the µLCR–β-neo construct (Fig. 2A). When
the HS-40 core sequence was added, the number of colonies
increased 130-fold to 52.5 ± 9.8% of µLCR–β-neo (Fig. 2B). In
K562 cells the number of colonies produced by the Aγ-neo
construct was 5.2 ± 2.8% of the colonies of the µLCR–Aγ-neo
construct (Fig. 3A). Addition of the HS-40 core to the Aγ-neo
construct increased the number of colonies 11-fold, to 57.2 ± 6.1%
of the µLCR–Aγ-neo (Fig. 3B). These results showed that HS-40
is a strong enhancer of β- and γ-globin gene expression.
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Figure 3. Interaction of HS-40 with the γ gene promoter and regulatory
elements of the β locus LCR. The γ-neo containing constructs were transfected
in K562 cells. The number of colonies produced are expressed as percent of the
control µLCR γ-neo. (A) γ-neo construct without enhancer. (B) HS-40–γ-neo.
(C) HS-40–HS1–γ-neo. (D) HS-40–HS2–γ-neo. (E) HS-40–nLCR–γ-neo. (F)
nLCR–γ-neo. Notice that the number of colonies produced by HS-40–γ-neo is
>50% of those produced by µLCR–γ-neo and that there is no cooperation
between HS-40 and the DNase I hypersensitive sites of the β LCR [compare (B)
with (C), (D) and (E)]. Also notice that in contrast to the results obtained with
the β gene promoter-containing HS-40 constructs (Fig. 2), the LCR elements
do not inhibit the interactions between HS-40 and the γ gene promoter.

Figure 4. Tandem arrangements decrease enhancer activity of the HS-40 core
in MEL cells. (A) β-neo construct without enhancer. (B) Tandemly arranged
HS-40s in the HS-40–HS-40–β-neo construct. (C) Two HS-40 bracketing the
β-neo gene in the HS-40–β-neo–HS-40 construct. (D) HS-40–β-neo control.
Notice that the tandem arrangement of the HS-40 elements strikingly inhibits
enhancer function while the placement of two HS-40 sequences, one 5′ and the
other 3′ to the β-neo gene does not decrease enhancer activity.

Interactions of the HS-40 with DNase I hypersensitive
sites of the β locus LCR
Additive or synergistic effects between HS-40 and elements of
the β-globin LCR would be useful in the design of globin gene
therapeutic vectors. We therefore examined whether combinations of the HS-40 core with the core elements of the DNase I
hypersensitive sites of the β locus LCR, or the addition of HS-40
to a 1.1 kb nanoLCR cassette, would further increase globin gene
expression. The 1.1 kb nLCR cassette contains the core elements
of the HS2, HS3, HS4 of the β locus LCR (21). The HS-40
core-containing recombinants HS-40 + HS1 β (or γ)-neo, HS-40
+ HS2 β (or γ)-neo, and nLCR + HS-40–β- (or γ)-neo shown in
Figure 1B were constructed.
Figure 2 shows the effects of combinations of these regulatory
elements on the β gene promoter following transfection of MEL
cells. While the number of colonies produced by the HS-40–β-neo
construct was 52.5% of µLCR–β-neo, the combination of HS-40
with HS1 decreased the number of colonies to 6.3% ± 1.9 of
µLCR–β neo (Fig. 2C). The combination of HS-40 with HS2
decreased the number of colonies to 20% ± 4.3 of the µLCR–β-neo
(Fig. 2D), while the combination of HS-40 with nLCR decreased
the number of colonies to 13.3% ± 2.9 of µLCR–β-neo (Fig. 2E).
The control construct nLCR–β-neo alone produced 64% ± 8.9 of
the number of colonies of the µLCR (Fig. 2F).
The effect of combinations of HS-40 with elements of the LCR
on γ gene promoter was tested following transfection of K562
cells. The combination of HS-40 with HS-1 produced a number
of colonies (62% ± 4.3 of µLCR–γ-neo, Fig. 3C) which was
similar to those produced by HS-40–γ-neo (Fig. 2B). Similarly,
there was no significant difference in the number of colonies
produced by the HS-40–γ-neo construct and the combination of
HS-40 with HS-2 (compare Fig. 3D and B) or the combination of
HS-40 with the nLCR (Fig. 3E). Thus, HS-40 appears to interact
differently with the β or the γ gene promoter in the presence of

Figure 5. Tandem arrangements decrease the enhancer activity of HS-40 core
in K562 cells. (A) γ-neo construct without enhancer. (B) HS-40–HS-40–γ-neo.
(C) HS-40–γ-neo–HS-40. (D) HS-40–γ-neo control.

elements of the β locus LCR. The presence of LCR elements
apparently inhibit the interaction between HS-40 and the β gene
promoter in an adult erythroid transcriptional milieu while they
do not affect the interaction between the HS-40 and the γ
promoter in a fetal-like erythroid transcriptional environment.
Tandem arrangements of HS-40
To test whether multiple copies of the HS-40 increase enhancer
activity, two copies of the HS-40 core were inserted upstream of
the β or γ promoter (Fig. 1B), and the constructs were tested in
MEL and K562 cells. The number of colonies produced by the
construct HS-40 + HS-40–β-neo was only 10% ± 4 of the
µLCR–β-neo (Fig. 4B) while the number produced by HS-40 +
HS-40–γ-neo was 9.6% ± 2.4 of µLCR–γ-neo (Fig. 5B). These
results suggest that tandem arrangements of the HS-40 core
sequence may result in chromatin conformational changes which
affect its function as an enhancer.
To investigate whether the decrease in HS-40 enhancer activity
was due to the tandem arrangement of two HS-40 core sequences,
the constructs HS-40–β-neo–HS-40 and HS-40–γ-neo–HS-40
(Fig. 1B) were used in colony assays. The number of colonies
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Figure 6. Chromatin structure of constructs transfected in MEL cells. DNase
I hypersensitive site assays were performed on pools of G418 clones containing
the indicated constructs. Parental band (P) and HSs associated with β-globin
promoter (Pr), HS-40 (H) and the neoR (n) gene are indicated for each
construct. The arrows above each blot indicate increasing DNase I concentration. The schematic diagram shows the location of HSs for the HS-40/β-globin
promoter/neoR gene construct (large arrows) and the probe used in Southern
blots. The small arrows indicate cut sites for restriction enzymes used to excise
the construct from genomic DNA (see Materials and Methods). M, molecular
weight markers (2.3, 2.0, 1.4, 1.1, 0.9 and 0.6 kb).

Figure 7. Chromatin structure of constructs in transfected K562 cells. DNase
I hypersensitive site assays were performed on pools of G418 clones containing
the indicated constructs. Parental band (P) and HSs associated with γ-globin
promoter (Pr), HS-40 (H) and the neoR (n) gene are indicated for each
construct. The arrows above each blot indicate increasing DNase I concentration. The schematic diagram shows the location of HSs for the HS-40/γ-globin
promoter/neoR gene construct (large arrows) and the probe used in Southern
blots. The small arrows indicate cut sites for restriction enzymes used to excise
the construct from genomic DNA (see Materials and Methods). M, molecular
weight markers (2.3, 2.0, 1.4, 1.1, 0.9 and 0.6 kb).

produced by HS-40–β-neo–HS-40 was 47% ± 12.0 of the
µLCR–β-neo (Fig. 4C), i.e., similar to the number obtained with
the HS-40–β-neo construct. The number of colonies produced by
HS-40–γ-neo–HS-40 was 47.3% ± 3.6 (Fig. 5C), i.e., was close
to the number produced by the HS-40–γ-neo.

in the production of a γ-globin expressing retroviral vector.
Incorporation of HS-40 into the LTRs of this vector resulted in
genetically stable, high-titre viruses which, in a limited number of
MEL cell clones, produced γ-globin mRNA levels equivalent to
the endogenous β-major globin gene (29). We have utilized the
neomycin resistance colony forming assay of Moon and Ley to test
a variety of β- and γ-globin promoter constructs containing HS-40
alone and in combination with other enhancers. This colony assay
allows the rapid screening of constructs in a chromatin context and
uses erythroleukemia cells which have not been induced by
reagents promoting erythroid differentiation and therefore retain
their proliferative potential. The use of uninduced cells represents
an important difference from conventional assays measuring
globin gene expression at the globin mRNA or the globin protein
levels in transgenic mice or in induced erythroleukemia cells. The
latter assays are done in terminally differentiated erythroid cells
that have lost their proliferative capacity and most likely have
different transcriptional environments compared to the uninduced
erythroleukemia cells.
Our data support previous results (20,30) suggesting that
HS-40 is a regulatory element able to interact with both
homologous and heterologous promoters. In contrast to the core
elements of the individual DNase I hypersensitive sites of the β
locus LCR which show minimal enhancer activity in the colony
assay of Moon and Ley (21), the HS-40 displays 50–60% of the
activity of control constructs containing a 2.5 kb µLCR cassette.
It is presently assumed that in addition to their other functions,
DNase I hypersensitive sites 2, 3 and 4 of the β locus LCR also
function as globin gene enhancers when they are stably integrated
into the genomes of erythroleukemia lines or in transgenic mice.
Our results suggest that as assessed by the colony assay, HS-40
displays higher enhancer activity compared to the individual core
elements of the β locus LCR.
Previous studies in transgenic mice and in transfected MEL
cells have shown that the enhancer activity of the β locus control
region represents the cooperative interaction between DNase I
hypersensitive sites 1–4 (3,31). We therefore examined whether
combinations of HS-40 with DNase I hypersensitive sites of the

Chromatin structure of integrated HS-40 constructs
To further characterize the function of HS-40 constructs we
performed DNase I sensitivity assays to monitor the formation of
DNase I hypersensitive sites within the stably transfected
recombinants. We were particularly interested to see whether the
double HS-40 constructs would exhibit an altered chromatin
structure. Pools of G418-resistant clones for β- (or γ)-neo,
HS-40–β- (or γ)-neo, and HS-40/HS-40–β- (or γ)-neo constructs
were tested. The location of the observed DNase I hypersensitive
sites and the Southern blot probes used are shown schematically
in Figures 6 and 7. In all constructs containing HS-40, a DNase
I hypersensitive site is created in the position of this element.
Similarly, all constructs containing a β- or γ-globin promoter form
DNase I hypersensitive sites over approximately –100 to –200 bp
of the β or γ promoters. A third DNase I hypersensitive site
located at approximately +350 bp of the neoR coding sequence is
also formed. Notice, in Figures 6 and 7, that that this DNase
hypersensitive site is seen in all but the double HS-40 constructs.
These results suggest that the tandem arrangement of two HS-40
elements disrupts the formation of the chromatin structure which
is associated with efficient β-neo or γ-neo transcription.
DISCUSSION
Despite ongoing development, use of the elements of the β-globin
LCR has yet to yield a therapeutically useful β-globin gene transfer
vector. One approach to the further development of such vectors is
the utilization of alternate regulatory elements which are able to
drive high levels of expression of the genes of the erythroid lineage.
The HS-40, the major regulatory element of the α-globin locus is
one such candidate. Ren et al. (29) have used the HS-40 element
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LCR further increase the enhancer activity of HS-40. We found
that the HS-40 fails to cooperate with the core elements of the
DNase I hypersensitive sites of the LCR. Instead of increasing
enhancer activity, the presence of HS1, or of HS2, or of a 1.1 kb
cassette containing the core sequences of HS2, HS3 and HS4,
inhibited the enhancer activity of HS-40 in transfected MEL cells.
There was no cooperation (but also no inhibition) of enhancer
activity between HS-40 and the core element of the LCR in γ gene
promoter constructs tested in K562 cells. The lack of cooperation
between HS-40 and the elements of the LCR adds to the growing
evidence that HS-40 is a regulatory element distinctively different
from the β locus LCR. Thus, although HS-40 is responsible for
the erythroid lineage-specific expression of α-globin genes, it
does not protect the α-globin transgenes from the effects of the
position of integration. Furthermore, HS-40 driven α-globin gene
expression is not developmentally stable in transgenic mice,
being 2–4-fold lower in adult transgenic animals compared to
transgenic embryos (14,32,33). Craddock et al. (34) have further
observed that, in contrast to the β-globin locus LCR, HS-40 exerts
no discernible effect on long-range chromatin structure, and in
addition, does not influence the formation of DNase I hypersensitive sites at the α-globin gene promoter.
It is established that tandem arrangements of enhancer
sequences increase the activity of classical enhancers (35–38). To
test whether HS-40 behaves similarly to classical enhancers,
constructs containing tandem arrangements of the 255 bp HS-40
core sequence were produced and tested in the colony assay of
Moon and Ley. Surprisingly, we found that in both K562 and
MEL cells, tandem arrangements of the HS-40 core decreased the
HS-40 enhancer activity significantly. The apparent interpretation of the results is that the tandem arrangement of the HS-40
core sequence result in chromatin conformational changes which
affect its interaction with the globin gene promoter. The reason for
this negative effect remains obscure. Inhibition of enhancer
function requires a tandem arrangement of the HS-40 core
sequences because placement of two HS-40 cores, one at the 5′
and the other of the 3′ end of the γ-neo or β-neo constructs does
not result in inhibition of the HS-40 enhancer function. These
results suggest that the presence of two HS-40 elements disrupts
the formation of a chromatin structure associated with efficient
transcription of the γ-neo or β-neo genes resulting in the
decreased colony formation. Our studies of the chromatin
structure of the HS-40 constructs support this conclusion as a
specific DNase I hypersenstive site, located within the proximal
neoR gene, is lost in cells containing the tandem HS-40 element.
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